Kancera
1.722 SEK -0.35%Be the first to follow this company
Kancera is a pharmaceutical company. The company develops pharmaceuticals that counteract injuries in acute and chronic inflammation. The products are developed primarily to counteract hyper-inflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe virus infections. Kancera is planning two Phase II clinical trials, in covid-19 and in cardiac patients. Kancera conducts research and development within Karolinska Institutet Science Park in Stockholm.
Read moreRevenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
KAN
Daily low / high price
1.652 / 1.728
SEK
Market cap
208.68M SEK
Turnover
137.63K SEK
Volume
80K
Latest videos
Financial calendar
Interim report
23.08.2024
Interim report
15.11.2024
Annual report
21.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 8.9 % | 8.9 % |
Nordnet Pensionsförsäkring | 1.5 % | 1.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Phase Ib completed and the recommended phase II dose is set in the ongoing KANDOVA study
Redeye: Kancera - Underestimated optionality
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools